Stoke Therapeutics, Inc.
STOKFigures shown here come from public SEC filings. Dates beside each section show the available history.
How Stoke Therapeutics, Inc. Makes Money
Follow each dollar of revenue through to what shareholders keep.
From revenue to net income
Pick a year or quarter. Each band's width is its dollar amount.
Financial Summary
Choose a year or quarter, compare it with the same period a year earlier, and open any row for its full filing history.
Loading financial history…
SEC filings supply these figures; updates after the dates shown are not included. This page includes 8 annual periods. The latest annual period ends Dec 31, 2025. The latest insider filing shown is dated Jun 18, 2026. The latest institutional report shown is dated Mar 31, 2026; other ownership filings may exist.
Ownership
Who holds the shares, as reported in SEC ownership filings.
Reported 13F positions
Each row shows what a filer reported for one date, not a current position. The link opens that filing.
| Filer | Report date | Shares | Value | Filing |
|---|---|---|---|---|
| Quadrature Capital Ltd | 2026-03-31 | 10,293 | $335K | SEC filing |
| Parkman Healthcare Partners LLC | 2026-03-31 | 336,519 | $11M | SEC filing |
| State of New Jersey Common Pension Fund D | 2026-03-31 | 13,664 | $445K | SEC filing |
| LRI Investments, LLC | 2026-03-31 | 146 | $4.75K | SEC filing |
| LPL Financial LLC | 2026-03-31 | 36,047 | $1.17M | SEC filing |
| PRINCIPAL FINANCIAL GROUP INC | 2026-03-31 | 63,933 | $2.08M | SEC filing |
| ROYAL BANK OF CANADA | 2026-03-31 | 458 | $15K | SEC filing |
| SIMPLEX TRADING, LLC | 2026-03-31 | 130 | $4.23K | SEC filing |
| INTECH INVESTMENT MANAGEMENT LLC | 2026-03-31 | 14,494 | $472K | SEC filing |
| Harvest Investment Services, LLC | 2026-03-31 | 62,838 | $2.05M | SEC filing |
| Caitong International Asset Management Co., Ltd | 2026-03-31 | 5,662 | $184K | SEC filing |
| MetLife Investment Management, LLC | 2026-03-31 | 26,106 | $850K | SEC filing |
| AMERIPRISE FINANCIAL INC | 2026-03-31 | 18,113 | $590K | SEC filing |
| Campbell & CO Investment Adviser LLC | 2026-03-31 | 15,049 | $490K | SEC filing |
| Rhenman & Partners Asset Management AB | 2026-03-31 | 83,000 | $2.7M | SEC filing |
| VALLEY NATIONAL ADVISERS INC | 2026-03-31 | 750 | Not shown | SEC filing |
| Smartleaf Asset Management LLC | 2026-03-31 | 155 | $4.92K | SEC filing |
| NISA INVESTMENT ADVISORS, LLC | 2026-03-31 | 2,838 | $92.4K | SEC filing |
| China Universal Asset Management Co., Ltd. | 2026-03-31 | 15,136 | $493K | SEC filing |
| WELLINGTON MANAGEMENT GROUP LLP | 2026-03-31 | 3,095,700 | $101M | SEC filing |
- Each value is checked against Stoke Therapeutics, Inc.'s share prices from within about three months of its report date (insiders' Form 4 trades and the latest close).
- Value not shown for 1 row: the filed value is about 1,000 times too small for the share count at Stoke Therapeutics, Inc.'s share price.
120 filers have only one report here.
Unusually large insider trades
Each trade is compared with the other insider trades of the same kind in the same security among Stoke Therapeutics, Inc.'s recent filings on file. Size alone is context, not a prediction or evidence of improper trading.
- 2026-03-10 · Krainer Adrian R.: Larger than 103 of the 109 other insider sales of Common Stock on file. SEC filing
- 2025-11-24 · Krainer Adrian R.: Larger than 104 of the 109 other insider sales of Common Stock on file. SEC filing
- 2025-11-14 · Krainer Adrian R.: Larger than 99 of the 109 other insider sales of Common Stock on file. SEC filing
- 2025-11-14 · Krainer Adrian R.: Larger than 100 of the 109 other insider sales of Common Stock on file. SEC filing
- 2025-10-08 · Kaye Edward M. MD: Larger than 102 of the 109 other insider sales of Common Stock on file. SEC filing
- 2025-10-03 · Kaye Edward M. MD: Larger than 105 of the 109 other insider sales of Common Stock on file. SEC filing
- 2025-09-03 · Kaye Edward M. MD: Larger than 106 of the 109 other insider sales of Common Stock on file. SEC filing
- 2025-06-04 · Ezbon International Ltd: Larger than all 109 other insider sales of Common Stock on file. SEC filing
- 2025-05-02 · Ticho Barry: Larger than 101 of the 109 other insider sales of Common Stock on file. SEC filing
- 2024-12-23 · Ezbon International Ltd: Larger than 108 of the 109 other insider sales of Common Stock on file. SEC filing
- 2024-09-19 · Ezbon International Ltd: Larger than 107 of the 109 other insider sales of Common Stock on file. SEC filing
Purchases & sales (open market or private)
| Security | Code | Price | Filing | |||
|---|---|---|---|---|---|---|
| 2026-06-16 | Allan Jonathan · GENERAL COUNSEL & CORP SEC | Common Stock | S — Open market or private sale | −1,457 | 29.95 | SEC filing |
| 2026-06-01 | Ticho Barry · CHIEF MEDICAL OFFICER | Common Stock | S — Open market or private sale | −1,795 | 30.58 | SEC filing |
| 2026-05-01 | Ticho Barry · CHIEF MEDICAL OFFICER | Common Stock | S — Open market or private sale | −2,243 | 32.79 | SEC filing |
| 2026-04-01 | Ticho Barry · CHIEF MEDICAL OFFICER | Common Stock | S — Open market or private sale | −1,838 | 32.66 | SEC filing |
| 2026-03-20 | Allan Jonathan · GENERAL COUNSEL & CORP SEC | Common Stock | S — Open market or private sale | −601 | 34.41 | SEC filing |
| 2026-03-20 | Allan Jonathan · GENERAL COUNSEL & CORP SEC | Common Stock | S — Open market or private sale | −8,692 | 33.64 | SEC filing |
| 2026-03-19 | Ticho Barry · CHIEF MEDICAL OFFICER | Common Stock | S — Open market or private sale | −1,461 | 29.99 | SEC filing |
| 2026-03-18 | Hoitt Jason · Chief Patient Officer | Common Stock | S — Open market or private sale | −1,762 | 31.28 | SEC filing |
Showing 8 of 10 rows
Grants, exercises, tax & gifts
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2026-06-03 | LEVIN ARTHUR A · Director | Director Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +17,786 | SEC filing |
| 2026-06-03 | TZIANABOS ARTHUR · Director | Director Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +17,786 | SEC filing |
| 2026-06-03 | Harrison Seth Loring · Director | Director Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +17,786 | SEC filing |
| 2026-06-03 | Krainer Adrian R. · Director | Director Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +17,786 | SEC filing |
| 2026-06-03 | Burstein Jennifer · Director | Director Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +17,786 | SEC filing |
| 2026-06-03 | Kaye Edward M. MD · Director | Director Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +17,786 | SEC filing |
| 2026-06-03 | Smith Julie · Director | Director Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +17,786 | SEC filing |
| 2026-04-03 | Kahn Clare · Director | Stock Option (Right to Buy) | A — Grant, award, or other acquisition | +30,782 | SEC filing |
Showing 8 of 20 rows
Other activity
| Security | Code | Filing | |||
|---|---|---|---|---|---|
| 2025-09-04 | Kaye Edward M. MD · Director | Restricted Stock Units | D — Disposition to the issuer | −144,000 | SEC filing |
| 2025-09-04 | Kaye Edward M. MD · Director | Employee Stock Option (Right to Buy) | D — Disposition to the issuer | −178,500 | SEC filing |
Showing 2 of 2 rows
These tables describe filed transactions, not current holdings. Prices are shown as filed; a currency is added only when the filing's data names one. Amended and possible duplicate rows are left out of size comparisons and transaction groups.